A randomised, prospective study, assessing changes in cerebral function in treatment naive HIV-1 infected subjects commencing either boosted atazanavir with Truvada or boosted darunavir with maraviroc
Design and Objective
When commencing antiretroviral therapy for the first time, improvements in brain function are frequently observed. However, whether these improvements may differ between different anti-HIV therapies is largely unknown. The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in brain function are observed over this period.
Key inclusion criteria
HIV-1 infected males or females, aged 18 years or above, with no previous antiretroviral treatment since HIV diagnosis.